Investigations

  • Girard Sharp is investigating reports that Maxar Technologies may have violated state and federal law by making false and misleading statements regarding the company’s business, operational and compliance policies.

    Maxar is alleged to have improperly inflated the value of its intangible assets, among other accounting improprieties.

  • Girard Sharp is investigating reports that certain Allergan BIOCELL© breast implants may cause anaplastic large cell lymphoma (“BIA-ALCL”), a cancer of the immune system.

    The FDA sought a worldwide recall of BIOCELL© implants in July 2019.

Pending Cases

  • Girard Sharp has filed a class action lawsuit following reports that certain Allergan BIOCELL© breast implants may cause anaplastic large cell lymphoma (“BIA-ALCL”), a cancer of the immune system. Access a copy of the complaint here.

    Allergan implemented a worldwide recall of BIOCELL© implants in July 2019.

  • Girard Sharp has jointly filed a class action complaint asserting that DXC Technology Corporation violated federal law by making false and misleading statements and omissions about the benefits from its “strategic roadmap” for conducting business following its merger with Computer Sciences Corporation. If you are a current or former shareholder of DXC Technology Corporation (NYSE Ticker: DXC), you may be entitled to compensation.

Results

  • $104.75 million settlement reached on the eve of trial on behalf of purchasers of the prescription drug Lidoderm.

  • Jay Peak EB-5 Fraud

    $150 million partial settlement recovered for investors in various Jay Peak EB-5 Immigrant Investor Program project offerings, whose funds were diverted for unauthorized uses.

Main Menu